Atea Pharmaceuticals (AVIR) Insider Polsky Buys 29,600 Shares

Bruce Polsky Acquires AVIR Shares in June Trading Wave

Bruce Polsky acquired 29,600 shares of Atea Pharmaceuticals, Inc. (NasdaqGS: AVIR) on June 18, 2026. The transaction added to a busy day of executive trades at the clinical-stage biopharmaceutical firm, which saw multiple insiders buying and selling shares simultaneously.

A Closer Look at the Insider Trading Activity

The June 18 session brought a rush of filings detailing moves across the executive team. Franklin Berger picked up 29,600 shares and also parted with 29,600 shares on the exact same date. Polly Murphy disposed of 29,600 shares. Bruno Lucidi sold 29,600 shares while separately picking up 26,700 shares. Meanwhile, Howard Berman added 37,700 shares to his personal holdings.

Stock Performance and Recent Market Levels

The shares trade in a market where valuations reflect the typical path of clinical-stage drug developers. The company has a market capitalization near $434.5 million. Because it focuses on early-stage therapeutics without commercial product sales yet, it carries a negative forward price-to-earnings ratio.

Analysts Set New Price Targets

Analyst updates offer context on how Wall Street views the pipeline progress. On August 13, 2026, Morgan Stanley maintained its equal weight rating on the stock while lifting its price target from $6.00 to $7.00. Across the broader analyst community, the stock holds a consensus target mean price of $9.42, with estimates ranging from a low of $7.00 to a high of $11.25 based on three analyst opinions.

Inside Atea Pharmaceuticals

Based in Boston, Massachusetts, Atea Pharmaceuticals discovers and develops oral antiviral medicines for serious viral infections. Its lead clinical work centers on treatments for hepatitis C and chronic viral conditions using proprietary nucleotide technology. The firm works to advance these therapeutic candidates through mid and late-stage clinical testing.

What Lies Ahead for AVIR

Market watchers will look toward the company's next scheduled earnings report, which is expected around November 11, 2026, for further updates on its clinical trials and financial standing. Insider filings will continue to provide a window into how executives manage their personal holdings in the biotech firm.